# Advent Life Sciences

> London-based transatlantic specialist life-sciences venture and growth investor. British Business Bank separately announced September 2026 commitments to its early-stage Fund IV and Growth Fund. These were LP commitments, not announced completed fund closes. The manager also co-led T-Therapeutics' $133M Series B in November 2026.

## Profile

- **Stage-based planning range:** $1M–$10M
- **Check-size evidence basis:** estimated
- **Founded:** N/A
- **Headquarters:** London, UK
- **AUM:** N/A
- **Rounds they lead:** N/A
- **Rounds they invest:** Seed, Series A, Series B, Series C, Growth

## Links

- [Website](https://adventls.com/)

## In-depth investment analysis

## Investment strategy
Advent Life Sciences backs medicines, medtech and life-sciences platform companies in the UK, Europe and US. It is distinct from [Advent International](/fund/advent-international), the buyout investor.

## Fund history and 2026 vehicle distinction
British Business Bank reports earlier backing of the 2019-vintage Advent Life Sciences Fund III, followed by two distinct vehicles: [Fund IV](/fund/advent-life-sciences-fund-iv), targeting early-stage development, and [Advent Life Sciences Growth Fund](/fund/advent-life-sciences-growth-fund), backing clinical progress and nontherapeutic commercial scale-up. September 2026 bank allocations of about €69.8M **agreed** to Fund IV and €87.2M **committed** to Growth Fund are one LP's allocations, not each fund's total capital or a legal closing event.

## Founder fit and diligence
Early biotech teams should demonstrate target validation, patents and runway to next clinical decision. A growth-stage company should provide trial milestones or repeatable commercial economics, with realistic regulatory and market access assumptions. These are illustrative requirements aligned with published mandates, not claimed official eligibility checklists. No universal fund-specific cheque size, carry or management fee has been verified.

## Reported portfolio context
The LP includes KaNDy Therapeutics, Nalu Medical, Miro Therapeutics, Levicept, Axonics and Cyted Health among **historical manager** investments, not verified Fund IV/Growth holdings. Advent separately co-led T-Therapeutics' $133M November 2026 Series B; portfolio funding is not GP fundraising.

Sources: [Bank commitment announcement](https://www.british-business-bank.co.uk/news-and-events/news/british-business-bank-agrees-commit-ps135m-two-new-advent-life-sciences-funds), [Fund IV listing](https://www.british-business-bank.co.uk/venture-link/advent-life-sciences-iv-fund), [Growth Fund listing](https://www.british-business-bank.co.uk/venture-link/advent-life-sciences-growth-fund).

## Research sources

- [Institutional LP statement](https://www.british-business-bank.co.uk/news-and-events/news/british-business-bank-agrees-commit-ps135m-two-new-advent-life-sciences-funds)
- [Fund IV listing](https://www.british-business-bank.co.uk/venture-link/advent-life-sciences-iv-fund)
- [Growth listing](https://www.british-business-bank.co.uk/venture-link/advent-life-sciences-growth-fund)

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/fund/advent-life-sciences